Avoid buying the dip in IBM following its negative earnings pre-announcement, as it signals a broader contraction in corporate IT spending that could weigh on the entire tech sector. Consider a short position on Bristol Myers Squibb (BMY) due to a failing product pipeline and looming revenue cliffs for its core franchises. Take a bearish stance on Micron (MU) and the memory sector, as the IBM news suggests cyclical risks for hardware spending are being underestimated. For a high-conviction long opportunity, look to Alnylam (ALNY), which is currently viewed as significantly undervalued. Conversely, look for a contrarian entry point in Adobe (ADBE) on its recent weakness, as its fundamental business model remains stronger than enterprise peers like IBM.

IBM (IBM)

• IBM pre-announced negative earnings, which was described as a "dangerous sign" and a potential bellwether for the broader economy. • The stock dropped approximately 22-24% following the news. • While some attribute the miss to a shift in spending toward AI, the sentiment expressed is that IBM is poorly positioned and its failure reflects poorly on corporate IT spending and business conditions.

Takeaways

• Bearish Sentiment: The speaker views IBM as a "stinker" and a warning sign for the entire economy. • Economic Indicator: IBM's poor performance is seen as a negative signal for global business conditions, outweighing positive CPI data. • Avoid the "Dip": Explicitly advised against buying the IBM dip, suggesting the news is fundamentally bad for the sector.

Bristol Myers Squibb (BMY)

• The company's portfolio is described as a "disaster" and a "dog," with aging franchises like Eliquis and Opdivo facing revenue cliffs and generic competition. • Recent acquisitions (e.g., Celgene) and new product launches (e.g., Sotyktu, Zeposia) are characterized as disappointing or failing to replace lost revenue. • Camzyos was noted as one of the few positive developments in the last five years.

Takeaways

• Short Opportunity: The speaker suggests BMY might be a viable short position due to a weak pipeline and "shitty launch portfolio." • Management Critique: Mentioned that the company hasn't had a good CEO in a long time and is struggling to digest large acquisitions.

Insmed (INSM)

• Discussed as a "monster stock" with significant recent success, particularly regarding its drug Brensocatib (referred to as "Brinsupri" in transcript) for non-CF bronchiectasis. • The drug trajectory is described as "fucking sick," with potential to become a $2B - $5B revenue product.

Takeaways

• High Valuation: With a market cap around $22B - $25B, the speaker questions how much upside remains, as massive revenue is already priced in. • Management Trust: Investment thesis rests on trusting management to continue recycling capital and finding new opportunities.

Micron (MU) & Semiconductor Sector

• The sector is currently "bifurcated." While memory companies (Micron, Hynix, SanDisk) are seeing massive rallies (Hynix up 17%, Micron up 5%), the speaker remains skeptical. • Micron was specifically targeted for a short trade during the stream.

Takeaways

• Bearish Lean: Despite the "nirvana" for memory companies, the speaker is "leaning bearish" and shorting MU, citing the IBM news as a negative catalyst for hardware spending. • Cyclical Risk: Warning that in cyclical companies, any sign of economic change (like the IBM miss) should be watched "like a hawk."

Adobe (ADBE)

• The stock fell 3-4% in sympathy with IBM’s pre-announcement. • The speaker noted that corporate spending is likely shifting away from Adobe toward AI infrastructure.

Takeaways

• Contrarian Buy: Despite the drop, the speaker mentioned "thinking about buying" the Adobe dip, noting that Adobe and IBM are fundamentally different companies.

Investment Themes & Other Mentions

AI and Software

• Palantir (PLTR), ServiceNow (NOW), and Workday (WDAY): All saw significant drops (5-10%) following the IBM news. They are viewed as comparables or partners to IBM’s enterprise services. • NVIDIA (NVDA): Experienced a "flash crash" during the stream but recovered. The speaker remains cautious about "Rubin" (next-gen chip) delays.

Biopharma Binaries & Small Caps

• 10x Genomics (TXG): Speaker is "leaning bearish" but hasn't finished the full analysis. • Alnylam (ALNY): Described as "super cheap" and a high-conviction long. • Tower Semiconductor (TSEM): Noted for a "huge beat" and positive outlook, leading to a 20% price surge. • HCA Healthcare (HCA): Pre-announced negative results, dragging down peers like Tenet Healthcare (THC).

Space & Private Equity

• SpaceX: Mentioned as a short-term short opportunity during a price bump, though the speaker expressed long-term belief in Elon Musk. • Rocket Lab (RKLB): Mentioned as being up slightly but not a major focus.

General Market Sentiment

• Bearish on Corporate Spend: The overarching theme is that IBM's failure signals a tightening of corporate IT budgets, which will eventually hit the broader tech sector. • Crypto: Viewed as a "gambler's" market; the speaker acknowledges projects like Hyperliquid but remains focused on "TradFi" and productive assets.